PCSK9 inhibitors: Going forward and beyond

被引：1
|
作者：
Attar, Armin [1 ]
机构：
[1] Shiraz Univ Med Sci, Dept Cardiovasc Med, TAHA Clin Trial Grp, Shiraz, Iran
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 08期
关键词：
LDL-CHOLESTEROL; SECONDARY ANALYSIS; CLINICAL-EFFICACY; EVOLOCUMAB; SAFETY; STATIN;
D O I：
10.1177/2047487320916964
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：803 / 804
页数：2
相关论文
共 50 条
  • [1] PCSK9 inhibitors
    Farnier, Michel
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2015, 19 (03): : 66 - 70
  • [2] PCSK9 inhibitors
    Farnier, Michel
    CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (03) : 251 - 258
  • [3] PCSK9 inhibitors
    Gencer, Baris
    Lambert, Gilles
    Mach, Francois
    SWISS MEDICAL WEEKLY, 2015, 145
  • [4] Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
    Safarova, Maya
    Bimal, Tia
    Soffer, Daniel E.
    Hirsh, Benjamin
    Shapiro, Michael D.
    Mintz, Guy
    Cha, Agnes
    Gianos, Eugenia
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 19
  • [5] PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
    不详
    EBIOMEDICINE, 2015, 2 (12): : 1835 - 1835
  • [6] Safety of PCSK9 inhibitors
    Grzesk, Grzegorz
    Dorota, Bednarska
    Wolowiec, Lukasz
    Wolowiec, Anna
    Osiak, Joanna
    Kozakiewicz, Mariusz
    Banach, Joanna
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 156
  • [7] Access to PCSK9 Inhibitors
    Baum, Seth J.
    Lepor, Norman E.
    Robinson, Jennifer G.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2018, 19 : S47 - S50
  • [8] Oral PCSK9 Inhibitors
    Anandita Agarwala
    Ramsha Asim
    Christie M. Ballantyne
    Current Atherosclerosis Reports, 2024, 26 : 147 - 152
  • [9] PCSK9 inhibitors are go
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (09) : 593 - 593
  • [10] Oral PCSK9 Inhibitors
    Agarwala, Anandita
    Asim, Ramsha
    Ballantyne, Christie M.
    CURRENT ATHEROSCLEROSIS REPORTS, 2024, 26 (05) : 147 - 152
12345